Log in

Start free trial
Test Utilization: Payment Policies More Effective than Practice Recommendations in Curbing Orders of Low-Value Tests

FDA Watch: Agency Resounds the Alarm on Biotin Test Interference

by | Nov 19, 2019 | Articles, Clinical Diagnostics Insider, Diagnostic Testing and Emerging Technologies, G2 Lab and Pathology Insider, Testing Trends-dtet

In early November 2019, the U.S. Food and Drug Administration (FDA) updated a previous safety communication about the potential of biotin to significantly interfere with diagnostic tests. The update reiterates the warning

Subscribe to View


Start a Free Trial for immediate access to this article


Try For Free
Already a member? Log in here